Canurta completes first tranche of strategic transaction with PharmaDrug
PharmaDrug acquires 19.9% equity interest in Canurta for 25,980,000 shares. Second tranche targets 40% ownership by March 2026. Canurta's CEO joins PharmaDrug's board.
Latest Canurta Therapeutics News & Updates
See the latest news and media coverage for Canurta. We track all announcements, press releases, and industry mentions in real time, all in one place.
AI-backed multi-target botanical therapies developer
canurta.com- Headquarters
- Mississauga, Canada
- Founded year
- 2021
- Company type
- Private company
- Number of employees
- 17–50
- Industry
- Biotechnology & Medical Research
Last updated
Latest news about Canurta Therapeutics (Canurta)
In short: Canurta launched Dual Relief Drops in the U.S., advanced its PharmaDrug merger, AI platform, and botanical drug research.
Company announcements
Canurta Therapeutics enters definitive agreement with PharmaDrug Inc.
PharmaDrug acquires up to 40% of Canurta's LP units in two tranches via share issuance. This accelerates growth and provides public market access. CEO Akeem Gardner joins PharmaDrug's board.
Canurta launches Satoshi Trials, advances CNR-401, expands public market strategy
Canurta signs LOI with PharmaDrug for up to 40% acquisition, launches Bitcoin-integrated Satoshi Trials, confirms CNR-401's blood-brain barrier penetration in preclinical study.
Canurta signs LOI with PharmaDrug to sell assets
The deal supports public listing, accelerates growth, provides capital access, and advances the Satoshi Trials. PharmaDrug may acquire up to 40% of Canurta by September 2025.
Media coverage
The Molecules Nobody Could Get Enough Of - CanadianSME Small Business Magazine
Canurta Therapeutics | Ontario, Canada | Botanical Drug Development For decades, a specific problem stalled an entire branch of pharmaceutical research. Certain rare polyphenols found...
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on...
PharmaDrug executes definitive agreement with Canurta Limited Partnership to buy 40% equity interest in Canurta
PharmaDrug Inc, a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines, announced that it has executed a definitive securities exchange...
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on...
Never miss news about Canurta
Track Canurta and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Canurta competitors & trending companies
Browse news for competitors to Canurta and other trending companies.
Annexon Biosciences
Oxcia
Spinogenix
Acelot
NextCell
NRG Therapeutics
Harness Therapeutics
Aquilus
Dunad
ResoTher Pharma
Aperture Therapeutics
Transposon Therapeutics
SharkNinja
NRx
Ropes & Gray
HighTech Kaunas
inretrn
Poundland
Farrer & Co
Specialfastigheter
SISAB
Hemsö
Stenvalvet
Liljewall
Veidekke
Locum
NCC
Kriminalvården
Archus
Nyréns
Peab
MVB
VGR fastigheter
AIX
ByggDialog
Tengbom